PMID- 25393640
OWN - NLM
STAT- MEDLINE
DCOM- 20150414
LR  - 20240213
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 100
IP  - 2
DP  - 2015 Feb
TI  - Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin 
      levels in patients with type 2 diabetes: a prospective pilot study.
PG  - 603-6
LID - 10.1210/jc.2014-2291 [doi]
AB  - CONTEXT: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering 
      agent whose effects on cardiovascular risk markers have not been fully 
      elucidated. OBJECTIVE: We evaluated the effect of liraglutide on markers of 
      oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients 
      with type-2 diabetes mellitus (T2DM). DESIGN AND SETTING: A prospective pilot 
      study of 2 months' duration has been performed at the Unit of Diabetes and 
      Cardiovascular Prevention at University of Palermo, Italy. Patients and 
      Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 +/- 
      13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) 
      in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver 
      disorders or renal failure were excluded. MAIN OUTCOME MEASURE(S): Plasma ghrelin 
      concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 
      were assessed. RESULTS: The addition of liraglutide resulted in a significant 
      decrease in glycated hemoglobin (HbA1c) (8.5 +/- 0.4 vs 7.5 +/- 0.4%, P < .0001). In 
      addition, plasma ghrelin and glutathione concentrations increased (8.2 +/- 4.1 vs 
      13.6 +/- 7.3 pg/ml, P = .0007 and 0.36 +/- 0.06 vs 0.44 +/- 0.07 nmol/ml, P = .0002, 
      respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 +/- 0.05 
      vs 0.04 +/- 0.07 pg/ml, P = .0487 and 7.7 +/- 7.7 vs 3.6 +/- 1.8 pg/ml, P = .0445, 
      respectively). These changes were not correlated with changes in fasting glycemia 
      or HbA1c. CONCLUSIONS: In a 2-months prospective pilot study, the addition of 
      liraglutide to metformin resulted in improvement in oxidative stress as well as 
      plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings 
      seemed to be independent of the known effects of liraglutide on glucose 
      metabolism.
FAU - Rizzo, Manfredi
AU  - Rizzo M
AD  - Biomedical Department of Internal Medicine and Medical Specialties (M.R., R.V.G., 
      D.N., G.M.), University of Palermo, Palermo 90127, Italy; Euro-Mediterranean 
      Institute of Science and Technology (M.R., A.M.G., I.B., G.L.V.), Palermo 90139, 
      Italy; Division of Endocrinology, Diabetes and Metabolism (M.R., A.A.R.), 
      University of South Carolina School of Medicine, Columbia, South Carolina 29203; 
      Division of Endocrinology (N.A., M.C.), The University of Texas Medical Branch, 
      Galveston, Texas 77555; Department of Experimental Biomedicine and Clinical 
      Neurosciences (A.M.G.), University of Palermo, Palermo 90127, Italy; Department 
      of Drug Sciences (I.B.), University of Catania, Catania 90125, Italy; Laboratory 
      for Molecular Genetics and Radiobiology (E.R.I.), Vinca Institute, University of 
      Belgrade, Belgrade 11000, Serbia; Department of Hypertension (M.B.), Medical 
      University of Lodz, Lodz 90-549, Poland; and Department of Biomedical and 
      Biotechnological Sciences (G.L.V.), University of Catania, Catania 90125, Italy.
FAU - Abate, Nicola
AU  - Abate N
FAU - Chandalia, Manisha
AU  - Chandalia M
FAU - Rizvi, Ali A
AU  - Rizvi AA
FAU - Giglio, Rosaria V
AU  - Giglio RV
FAU - Nikolic, Dragana
AU  - Nikolic D
FAU - Marino Gammazza, Antonella
AU  - Marino Gammazza A
FAU - Barbagallo, Ignazio
AU  - Barbagallo I
FAU - Isenovic, Esma R
AU  - Isenovic ER
FAU - Banach, Maciej
AU  - Banach M
FAU - Montalto, Giuseppe
AU  - Montalto G
FAU - Li Volti, Giovanni
AU  - Li Volti G
LA  - eng
SI  - ClinicalTrials.gov/NCT01715428
GR  - UL1 TR000071/TR/NCATS NIH HHS/United States
GR  - UL1TR000071/TR/NCATS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141113
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Ghrelin)
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9100L32L2N (Metformin)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Ghrelin/*blood
MH  - Glucagon-Like Peptide 1/*analogs & derivatives/pharmacology/therapeutic use
MH  - Heme Oxygenase-1/*blood
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Liraglutide
MH  - Male
MH  - Metformin/pharmacology/therapeutic use
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Pilot Projects
MH  - Prospective Studies
PMC - PMC4318909
EDAT- 2014/11/14 06:00
MHDA- 2015/04/15 06:00
PMCR- 2016/02/01
CRDT- 2014/11/14 06:00
PHST- 2014/11/14 06:00 [entrez]
PHST- 2014/11/14 06:00 [pubmed]
PHST- 2015/04/15 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 14-2291 [pii]
AID - 10.1210/jc.2014-2291 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2015 Feb;100(2):603-6. doi: 10.1210/jc.2014-2291. Epub 
      2014 Nov 13.